

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/068611 A1

(51) International Patent Classification⁷: C12N 5/06, 9/12

(21) International Application Number:
PCT/EP2004/000339

(22) International Filing Date: 19 January 2004 (19.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): **ADVANCED IN VITRO CELL TECHNOLOGIES, S.L.** [ES/ES]; Baldiri Reixac, 10-12, 08028 Barcelona (ES).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CASTELL RIPOLL, Jose Vicente** [ES/ES]; Baldiri Reixac, 10-12, 08028 Barcelona (ES). **JOVER ATIENZA, Ramiro** [ES/ES]; Baldiri Reixac, 10-12, 08028 Barcelona (ES). **GOMEZ-LECHON, Maria, Jose** [ES/ES]; Baldiri Reixac, 10-12, 08028 Barcelona (ES).

(74) Agent: **CARPINTERO LOPEZ, Francisco**; Herrero & Asociados, S.L., Alcala, 35, 28014 Madrid (ES).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR OBTAINING A SINGULAR CELL MODEL CAPABLE OF REPRODUCING IN VITRO THE METABOLIC IDIOSYNCRASY OF HUMANS

(57) Abstract: The method is based on the use of expression vectors coding for the sense and anti-sense mRNA of the Phase I and Phase II drug biotransformation enzymes showing a greatest variability in humans for transforming cells expressing reductase activity. Such vectors can modulate (increase or decrease) the individualised expression of an enzyme without affecting the other enzymes. This singular cell model can reproduce in vitro the metabolic idiosyncrasy of humans. It is applicable in the study of development of new drugs, specifically in the study of metabolism, potential idiosyncratic hepatotoxicity, medicament interactions, etc., of new drugs.

WO 2005/068611 A1